Joaquin Duato, worldwide chairman of pharmaceuticals at Johnson & Johnson, was elected chairman. Joseph Jimenez, chief executive officer of Novartis AG, was elected chairman-elect, and Amgen chairman and CEO Robert Bradway was named board treasurer.
“I am pleased to welcome Joaquin Duato, Joseph Jimenez and Robert Bradway to their new leadership roles at PhRMA and UCB as a new member,” PhRMA president and CEO Stephen Ubl said in a statement. “I, and our entire team, look forward to working with them to convene stakeholders across the health care system to discuss new innovative ways to pay for medicines and advance patient-focused solutions. Biopharmaceutical science is advancing faster than ever before, and we need to make sure we have a payment and reimbursement system that is as innovative as the medicines produced by our companies.”
Duato assumed the role of board chairman in early January after the departure of George Scangos, who stepped down as CEO of Biogen.
“I am honored to lead this talented executive team during such a pivotal time in defining the future of America’s health care system,” Duato commented. “Together with Steve Ubl, we will ensure that PhRMA is a collaborative and inclusive voice, bringing positive, pragmatic solutions forward to make our health care system work better for patients,” said Duato.
In addition to the election of new officers, PhRMA announced UCB Inc., based in Smyrna, Ga., as a new member. UCB Inc. is a division of Brussels, Belgium-based UCB, a global biopharmaceutical company with more than 7,500 employees in about 40 countries and sales of over $4 billion.
Jimenez has been CEO of Novartis since 2010. “For patients to truly benefit from the new era of medicine, there is a critical need for greater collaboration in the health care ecosystem,” he stated. “PhRMA is making important strides in this effort, and I look forward to more widely representing the industry in the move toward a value-driven health care system.”
Bradway has served as Amgen’s chairman since 2013 and as CEO since 2012. “Helping patients and addressing the burden of disease is what drives the men and women of this industry every single day,” he commented. “We are seeing the power of innovation in every aspect of today’s approaches to medical discovery and are eager to demonstrate how bold advancements in innovation can address the costs of disease.”